Citius Pharmaceuticals, Inc.: 10-K filed 2017-12-13

Name: Citius Pharmaceuticals, Inc.: 10-K filed 2017-12-13
Creator: Citius Pharmaceuticals, Inc.

What Citius Pharmaceuticals, Inc. reported in its annual report filed 2017-12-13 (fiscal FY 2017): 30 published measures, 76 facts as tagged in accession 0001213900-17-013191.

This filing

Form: 10-K (annual report)
Filed: 2017-12-13
Fiscal period: fiscal FY 2017
Accession: 0001213900-17-013191 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	24,416,553	USD
At 2016-09-30	21,950,341	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2017-09-30	21,947,388	USD
At 2016-09-30	16,766,383	USD
At 2015-09-30	-635,213	USD
At 2014-09-30	-741,935	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-09-30	3,204,108	USD
At 2016-09-30	294,351	USD
At 2016-06-30	1,626,140	USD
At 2015-09-30	676,137	USD
At 2014-09-30	1,552,060	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-10,384,953	USD	365
2015-10-01 to 2016-09-30	-8,295,698	USD	366
2014-10-01 to 2015-09-30	-2,902,268	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-7,971,205	USD	365
2015-10-01 to 2016-09-30	-5,900,421	USD	366
2014-10-01 to 2015-09-30	-2,385,416	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	2,126	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	10,883,088	USD	365
2015-10-01 to 2016-09-30	5,262,887	USD	366
2014-10-01 to 2015-09-30	1,509,493	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-2,126	USD	365
2015-10-01 to 2016-09-30	255,748	USD	366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-27,721,200	USD
At 2016-09-30	-17,336,247	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-09-30	3,236	USD
At 2016-09-30	3,742	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	986,620	USD	365
2015-10-01 to 2016-09-30	732,151	USD	366
2014-10-01 to 2015-09-30	486,271	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-9,986,311	USD	365
2015-10-01 to 2016-09-30	-7,449,291	USD	366
2014-10-01 to 2015-09-30	-3,229,929	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	3,424,354	USD
At 2016-09-30	892,835	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	850,789	USD	365
2015-10-01 to 2016-09-30	8,994	USD	366
2014-10-01 to 2015-09-30	7,500	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	2,469,165	USD
At 2016-09-30	5,183,958	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-09-30	602,431	USD
At 2016-09-30	909,156	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2017-09-30	1,586,796	USD
At 2016-09-30	1,586,796	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	9,986,311	USD	365
2015-10-01 to 2016-09-30	7,449,291	USD	366
2014-10-01 to 2015-09-30	3,229,929	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	2,936,252	USD	365
2015-10-01 to 2016-09-30	2,933,199	USD	366
2014-10-01 to 2015-09-30	1,797,045	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	8,345,844	shares
At 2016-09-30	4,875,871	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-09-30	49,660,242	USD
At 2016-09-30	34,097,754	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2017-09-30	10,648	USD
At 2016-09-30	8,522	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2017-09-30	7,412	USD
At 2016-09-30	4,780	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-09-30	560,918	USD
At 2016-09-30	958,101	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-10,384,953	USD	365
2015-10-01 to 2016-09-30	-8,295,698	USD	366
2014-10-01 to 2015-09-30	-2,902,268	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	6,063,439	USD	365
2015-10-01 to 2016-09-30	3,783,941	USD	366
2014-10-01 to 2015-09-30	946,613	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	2,632	USD	365
2015-10-01 to 2016-09-30	1,343	USD	366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-398,642	USD	365
2015-10-01 to 2016-09-30	-846,407	USD	366
2014-10-01 to 2015-09-30	327,661	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	1,133	USD	365
2015-10-01 to 2016-09-30	1,985	USD	366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-306,725	USD	365
2015-10-01 to 2016-09-30	105,230	USD	366
2014-10-01 to 2015-09-30	452,981	USD	365

Inspect the source

Entity: Citius Pharmaceuticals, Inc. / CIK 0001506251
Captured: 2026-09-20T09:12:24.553Z
SEC response SHA-256: dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))